guest ::
| Home > In process > Multimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies. > print |
| Home > In process > Multimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies. > print |
| 001 | 285740 | ||
| 005 | 20260320151751.0 | ||
| 024 | 7 | _ | |a 10.1016/j.parkreldis.2026.108265 |2 doi |
| 024 | 7 | _ | |a pmid:41780490 |2 pmid |
| 024 | 7 | _ | |a 1353-8020 |2 ISSN |
| 024 | 7 | _ | |a 1873-5126 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00297 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Hasoon, Jahfer |b 0 |
| 245 | _ | _ | |a Multimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2026 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1774016172_12449 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Predicting conversion to dementia in mild cognitive impairment with Lewy bodies (MCI-LB) remains challenging. Furthermore, there is limited research combining predictive markers in MCI-LB. We explored the utility of Lewy body and Alzheimer's disease biomarkers for the prediction of future decline in MCI-LB.Eighty-seven participants were included (35 MCI-AD, 15 possible MCI-LB, 37 probable MCI-LB). Baseline assessment involved MRI, EEG, bloods and cognitive testing. Follow up was completed yearly with review of diagnosis and repeat cognitive testing. We evaluated the relationship between baseline biomarkers and dementia-free survival time. We also investigated biomarker effects on future cognitive decline using annualised change in ACE-R. The value of combining biomarkers with baseline cognitive test score was assessed using forward selection.In probable MCI-LB, shorter dementia-free survival time was strongly associated with smaller hippocampal volume (hazard ratio = 2.36, 95% CI 1.41 - 3.94) and smaller posterior cortical volume (hazard ratio = 2.62, 95% CI 1.35 - 5.10). Reduced EEG dominant frequency, increased relative delta and theta power, reduced insula volume, increased plasma tau, and increased plasma GFAP were also associated with an increased hazard ratio. Posterior atrophy, hippocampal atrophy, and GFAP were significant predictors of ACE-R decline. Combining blood and MRI biomarkers improved model quality for dementia-free survival (GFAP and hippocampal atrophy) and cognitive test decline (AB ratio and posterior atrophy).Blood, EEG and MRI biomarkers of dementia with Lewy bodies, neurodegeneration and Alzheimer's co-pathology demonstrate utility for prognosis in MCI-LB. Combining biomarkers across modalities improves prognostic accuracy. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Dementia with lewy bodies |2 Other |
| 650 | _ | 7 | |a Disease progression |2 Other |
| 650 | _ | 7 | |a EEG |2 Other |
| 650 | _ | 7 | |a MRI |2 Other |
| 650 | _ | 7 | |a Mild cognitive impairment |2 Other |
| 650 | _ | 7 | |a Plasma biomarkers |2 Other |
| 700 | 1 | _ | |a Hamilton, Calum A |b 1 |
| 700 | 1 | _ | |a Firbank, Michael |b 2 |
| 700 | 1 | _ | |a Schumacher, Julia |0 P:(DE-2719)9002248 |b 3 |u dzne |
| 700 | 1 | _ | |a Colloby, Sean J |b 4 |
| 700 | 1 | _ | |a Donaghy, Paul C |b 5 |
| 700 | 1 | _ | |a Taylor, John-Paul |b 6 |
| 700 | 1 | _ | |a Thomas, Alan J |b 7 |
| 773 | _ | _ | |a 10.1016/j.parkreldis.2026.108265 |g Vol. 145, p. 108265 - |0 PERI:(DE-600)2027635-7 |p 108265 |t Parkinsonism & related disorders |v 145 |y 2026 |x 1353-8020 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285740/files/DZNE-2026-00297.pdf |y Restricted |
| 856 | 4 | _ | |u https://pub.dzne.de/record/285740/files/DZNE-2026-00297.pdf?subformat=pdfa |x pdfa |y Restricted |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)9002248 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-11-12 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PARKINSONISM RELAT D : 2022 |d 2025-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-11-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-11-12 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2025-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)5000014 |k AG Storch |l Non-Motor Symptoms in Parkinson's disease |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)5000014 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|